ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC trimmed its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 82.3% during the first quarter, HoldingsChannel reports. The fund owned 51,410 shares of the biopharmaceutical company’s stock after selling 238,701 shares during the quarter. Janus Henderson Group PLC’s holdings in ACADIA Pharmaceuticals were worth $1,145,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC increased its position in shares of ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 386 shares during the last quarter. Cetera Investment Advisers grew its stake in ACADIA Pharmaceuticals by 2.7% in the fourth quarter. Cetera Investment Advisers now owns 16,355 shares of the biopharmaceutical company’s stock worth $437,000 after purchasing an additional 436 shares in the last quarter. J.W. Cole Advisors Inc. grew its stake in ACADIA Pharmaceuticals by 2.5% in the fourth quarter. J.W. Cole Advisors Inc. now owns 20,632 shares of the biopharmaceutical company’s stock worth $551,000 after purchasing an additional 501 shares in the last quarter. Oregon Public Employees Retirement Fund increased its holdings in ACADIA Pharmaceuticals by 2.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 28,666 shares of the biopharmaceutical company’s stock valued at $766,000 after buying an additional 566 shares during the last quarter. Finally, Vise Technologies Inc. increased its holdings in ACADIA Pharmaceuticals by 4.0% in the third quarter. Vise Technologies Inc. now owns 15,367 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 585 shares during the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $26.13, for a total value of $432,660.54. Following the completion of the transaction, the executive vice president owned 18,994 shares in the company, valued at $496,313.22. This represents a 46.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Mark C. Schneyer sold 14,292 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $29.22, for a total transaction of $417,612.24. Following the transaction, the executive vice president directly owned 67,828 shares in the company, valued at approximately $1,981,934.16. The trade was a 17.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 42,100 shares of company stock valued at $1,134,287. Company insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD stock opened at $29.39 on Tuesday. ACADIA Pharmaceuticals Inc. has a 12-month low of $19.69 and a 12-month high of $29.65. The firm has a market capitalization of $5.06 billion, a price-to-earnings ratio of 13.24, a price-to-earnings-growth ratio of 23.76 and a beta of 0.81. The business has a 50 day simple moving average of $24.55 and a 200 day simple moving average of $23.28.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.11. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.The firm had revenue of $308.00 million for the quarter, compared to the consensus estimate of $296.55 million. During the same quarter in the previous year, the business earned $0.16 EPS. The firm’s revenue for the quarter was up 16.4% on a year-over-year basis. On average, equities analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $37.00 target price on shares of ACADIA Pharmaceuticals in a report on Monday, June 29th. BMO Capital Markets boosted their price target on ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, July 21st. HC Wainwright reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday. Wall Street Zen upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Stifel Nicolaus lifted their price objective on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the stock a “hold” rating in a report on Tuesday, July 21st. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.31.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.